Overview

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Status:
WITHDRAWN
Trial end date:
2022-05-23
Target enrollment:
Participant gender:
Summary
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
Phase:
PHASE2
Details
Lead Sponsor:
MedPacto, Inc.
Treatments:
Imatinib Mesylate
vactosertib